Autres langues Poolbeg Pharma PLC

Actions

Temps Différé London S.E. Autres places de cotation 10:13:58 07/06/2024			Varia. 5j.	Varia. 1 janv.
13,34 ^GBX	+2,26 %		-2,59 %	+47,46 %

01/05	Poolbeg Pharma obtient un brevet complet aux États-Unis pour son immunomodulateur II	MT
01/05	Poolbeg Pharma célèbre l'obtention d'un brevet complet pour l'Immunomodulateur II	AN

Poolbeg Pharma plc - Annual Report and AGM Notice	10/05
Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office	08/05
Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	01/05
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	01/05
Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug	01/05
Poolbeg Pharma plc - Appointment of Joint Broker	01/05
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	01/05
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	30/04
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	30/04
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79	30/04
Poolbeg Pharma PLC Reports Earnings Results for the Full Year Ended December 31, 2023	30/04
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	20/03
Poolbeg Pharma plc Announces POLB 001 US Patent Update	20/03
Poolbeg Pharma plc - Director Share Purchase	23/02
Poolbeg Pharma plc - Director Share Purchase	20/02
Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale	20/02
Diversified Energy offers dividend alternative	15/02
Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role	15/02
Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman	15/02
Katoro Gold launches fundraising, eyes board shake-up	12/02

Aucun résultat pour cette recherche